so the next trial ( a phase 2b dose ranging study) for cb-03-01 will be starting q4 2016. So just about any time in the next three months. They will be trialing doses of 2.5%, 5%, 7.5% BID, 7.5% ED and vehicle control. The study will have 400 participants and run for 12 months! There will also be an interim analyses at 6 months! Hopefully all goes smoothly! Here is the presentation: (it is in German)
http://www.cassiopea.com/~/media/Files/C/Cassiopea/presentations/CAS160920Investora 2016.pdf
http://www.cassiopea.com/~/media/Files/C/Cassiopea/presentations/CAS160920Investora 2016.pdf